Hyaluronic acid (topical): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Hyaluronic acid (topical)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(15 intermediate revisions by 2 users not shown)
Line 5: Line 5:
|drugClass=musculoskeletal agent
|drugClass=musculoskeletal agent
|indicationType=treatment
|indicationType=treatment
|indication=[[Osteoarthritis]] of knee, hair growth and loss prevention
|indication=[[osteoarthritis]] of knee, hair growth and loss prevention
|adverseReactions=injection site pain, injection site reaction , arthralgia  
|adverseReactions=injection site pain, injection site reaction , [[arthralgia]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 18: Line 18:
===Hyaluronic Acid Solution===
===Hyaluronic Acid Solution===


* For hair grower and loss prevention  
* For hair growth and loss prevention  


'''Dosage'''
'''Dosage'''
Line 38: Line 38:
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|warnings=* Stop using and see a doctor if any hypersensitivity symptom continues  
|warnings=* Stop using and see a doctor if any hypersensitivity symptom continues  
* Avoid storing under direct sung light or high temperature
* Avoid storing under direct sun light or high temperature
|clinicalTrials='''Dermatologic''': Injection site pain (2.5% ), Injection site reaction (0.2% )
|clinicalTrials='''Dermatologic''': Injection site pain, Injection site reaction  


'''Musculoskeletal''': [[Arthralgia]] (12.6% )
'''Musculoskeletal''': [[arthralgia]]
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 59: Line 59:
<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* IV
|administration=* IV
Intra-articular
:*Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only.


Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only.
:*If treatment is bilateral, use a separate syringe for each knee.
 
If treatment is bilateral, use a separate syringe for each knee.


* For hair scalp spraying only
* For hair scalp spraying only
|monitoring=* Reduction in pain associated with [[osteoarthritis]] of the knee is indicative of efficacy
|monitoring=* Reduction in pain associated with [[osteoarthritis]] of the knee is indicative of efficacy
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|drugBox=<!--Mechanism of Action-->
|drugBox=[[File:Hyaluronic acid drug.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
Line 75: Line 73:
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|brandNames=* Orthovisc
* Monovisc
* Morisu
|drugShortage=
|drugShortage=
}}
}}
{{PillImage
{{LabelImage}}
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}11.png
|fileName=Hyaluronic acid ingredients and appearance.png
}}
}}
<!--Pill Image-->
<!--Pill Image-->
Line 97: Line 93:


<!--Category-->
<!--Category-->
[[Category:Glycosaminoglycans]]


[[Category:Drug]]
[[Category:Drug]]

Latest revision as of 16:28, 20 August 2015

Hyaluronic acid (topical)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Hyaluronic acid (topical) is a musculoskeletal agent that is FDA approved for the treatment of osteoarthritis of knee, hair growth and loss prevention. Common adverse reactions include injection site pain, injection site reaction , arthralgia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Hyaluronic Acid Solution

  • For hair growth and loss prevention

Dosage

  • Spray on the scalp 2~3 times daily as needed
  • Recommendable to apply enough on the scalp prior to going to bed

Hyaluronic Acid Injection

  • Osteoarthritis of knee

Dosage

  • Osteoarthritis of knee: 30 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 3 to 4 injections (as a series of 3 to 4 injections each 1 week apart).

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Hyaluronic acid (topical) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients.

Contraindications

There is limited information regarding Hyaluronic acid (topical) Contraindications in the drug label.

Warnings

  • Stop using and see a doctor if any hypersensitivity symptom continues
  • Avoid storing under direct sun light or high temperature

Adverse Reactions

Clinical Trials Experience

Dermatologic: Injection site pain, Injection site reaction

Musculoskeletal: arthralgia

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Hyaluronic acid (topical) in the drug label.

Drug Interactions

There is limited information regarding Hyaluronic acid (topical) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Hyaluronic acid (topical) in women who are pregnant.
Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hyaluronic acid (topical) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Hyaluronic acid (topical) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Hyaluronic acid (topical) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Hyaluronic acid (topical) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • IV
  • Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only.
  • If treatment is bilateral, use a separate syringe for each knee.
  • For hair scalp spraying only

Monitoring

  • Reduction in pain associated with osteoarthritis of the knee is indicative of efficacy

IV Compatibility

There is limited information regarding IV Compatibility of Hyaluronic acid (topical) in the drug label.

Overdosage

There is limited information regarding Hyaluronic acid (topical) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

This image is provided by the National Library of Medicine.

Mechanism of Action

There is limited information regarding Hyaluronic acid (topical) Mechanism of Action in the drug label.

Structure

There is limited information regarding Hyaluronic acid (topical) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Hyaluronic acid (topical) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Hyaluronic acid (topical) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Hyaluronic acid (topical) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Hyaluronic acid (topical) in the drug label.

How Supplied

There is limited information regarding Hyaluronic acid (topical) How Supplied in the drug label.

Storage

There is limited information regarding Hyaluronic acid (topical) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Hyaluronic acid (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Hyaluronic acid (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Hyaluronic acid (topical) in the drug label.

Precautions with Alcohol

  • Alcohol-Hyaluronic acid (topical) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Orthovisc
  • Monovisc
  • Morisu

Look-Alike Drug Names

There is limited information regarding Hyaluronic acid (topical) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject: 

 |Label Page=Hyaluronic acid (topical)
 |Label Name=

}}

{{#subobject: 

 |Label Page=Hyaluronic acid (topical)
 |Label Name=Hyaluronic acid ingredients and appearance.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Hyaluronic_acid_(topical)&oldid=1136781"